poisar

Stock

Akari Therapeutics plc ADS AKTX

$7.54+7.71%

Overview

AKTX market data

Price History

AKTX price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.00
Diluted earnings per share over the trailing twelve months.
Beta
1.39
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.02 – $49.60
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $8.2M · P/B 0.31.

Company News

10 captured
Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCsBenzinga · Aug 13, 2026, 8:45 PM
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC InnovationGlobenewswire Inc · Aug 4, 2026, 1:15 PM
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 31, 2026, 8:49 AM
Akari Therapeutics Announces Strategic Research Collaboration With Whitehawk To Conduct Preclinical Studies Evaluating PH1 Spliceosome-Modulating Payload Technology In Combination With TOP1i ADC PlatformBenzinga · Jul 21, 2026, 11:15 AM
Maxim Group Upgrades Akari Therapeutics to Buy, Announces $30 Price TargetBenzinga · Jul 20, 2026, 6:15 PM
Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling ShareholdersBenzinga · Jul 2, 2026, 9:35 PM
8-K filing — Akari Therapeutics Plc (AKTX)SEC EDGAR · Jun 26, 2026, 9:15 PM
Akari Therapeutics CEO Highlights ASCO Data Demonstrating Synergy Of AKTX-101 With Adagasrib In KRAS-Driven Cancers In Virtual Investor "What This Means" SegmentBenzinga · May 28, 2026, 1:25 PM
VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga · May 26, 2026, 12:06 PM
Why Akari Therapeutics Stock Is Falling On Tuesday?Benzinga · May 26, 2026, 11:41 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock